Myricx Bio

Myricx Bio is a clinical-stage biotechnology company developing a novel class of payloads for antibody-drug conjugates based on inhibition of N-myristoyltransferase, an enzyme essential to cancer cell survival.

Its NMTi payload chemistry platform is designed to address limitations of existing ADC payloads, including resistance and tolerability, across multiple solid tumour types.

Spun out of Imperial College London and the Francis Crick Institute, the company is advancing a proprietary pipeline of NMTi-ADCs towards first-in-human studies.